

Cognitive Longevity Through Sound

Non-Conf. Investor Presentation
Q2 2026



Decreased mental activity
weakens neural pathways.

1 in 12 dementia cases are
due to untreated hearing loss.

The risk is **doubled** for those
struggling to hear in noisy places.

Source: 2024 update of the Lancet Commission on dementia

Hearing loss fuels social and
professional withdrawal.


There Are Two Kinds Of Hearing Loss

Problems in the Ear

(Peripheral Hearing Loss)

A volume problem.

Treatable with
hearing aids.



Problems in the Brainstem


(Central Hearing Loss)

A processing problem.

No treatments are
available.

We Set Out To Treat The Unaddressed Half Of Hearing Loss

Central hearing loss is when the brain isn't fast enough to distinguish between many sound sources. Hearing aids only amplify the problem.



Caused by deteriorating myelin sheaths on neurons in the auditory brainstem.

Our Breakthrough – LOOT Therapy

Localized Oligodendrocyte Optimization Therapy (LOOT)

Is the first ever treatment that reverses the neurological root cause.

30 Days of:

**Targeted Audio
Therapy**

**+ Oral Clemastine
Fumarate**

An FDA-approved antihistamine

Only this **combination**
works



Stimulates the brain to
repair myelin sheaths in the
auditory brainstem.

LOOT Will Be Sold Via A Proven Distribution Path

Patients Pay ENTs/Audiologist \$5k

Pay out of pocket. Like Lasik, GLP-1s, or Hearing Aids.



Clinician Pays Parley \$2.5k


Every hour **5,000 patients** are diagnosed with central hearing loss but clinicians **have no treatment available**



Parley provides complete solution at hearing aid prices.



DRM Protected Therapy Portal




Biomarker Monitoring Headphones



Drug

Defensibility is in our DNA



Patented Technology

- 2 provisional patents submitted
- Covers sound & drug remyelination
- Covers hardware & software protections
- Will convert into 5+ patents
- More IP ready to go



Neurologic Data Collection

- EEG data for our key biomarker
- Psychometric data for improvements
- Data collection during each therapy
- Personalized treatments forthcoming
- Data mining will drive innovations

Brain data collection is inherent

A Seasoned Team Steering The Ship



Samuel Budoff, PhD

CEO, Co-Founder

PhD Neuroscience

MS Neuroengineering

MS Statistics

8 years biotech startup experience

Founder BaconBio Inc, led team to patent



Achim Klug, PhD

CSO, Co-Founder

PhD Neurobiology / Zoology

Professor at UC Anschutz since 2009

12 Years neurotech startup experience

Founder PopNeuron, led team to revenue

Holds 3 US patents and 1 pending on LOOT



Unparalleled Understanding Of The Auditory Brain Earned Over 30 Years Leading the Field



Dr. Klug is one of the foremost experts on central hearing loss and developer of Parley's treatment.



Developed at:  Anschutz

#5

Medical research
university globally

15%

Of all current US clinical
trials take place at CU

Source: Nature Journal, 2025

7 Years Of Research Later

Sound + Drug Combo Patented, 90% Loss Reversal in Animals Demonstrated

2019



\$7M NIH Grant to Test Hypothesis

2023



Preclinical Studies Complete

Causal animal model proves root cause.
Treatment demonstrated with huge (1.5) effect size.

2025



Company formed, Patent Obtained

2 additional NIH animal study grants awarded.

2026



\$6M NIH Grant for Basic Science

Phase II Study Begins

Now Raising To Accelerate Trials And Test Market

Capital efficient with NIH funding and no dilutive capital raised until now

2026



FDA Phase II Clinical Trial

344 Patients at CU Anschutz
Measuring hearing improvement, safety already proven by other Phase II trials.



Montana Revenue Test

First in nation “right-to-try” bill allows clinics to sell any Phase I-cleared treatment

2027


Ready for Phase III & Series A



Montana Profits Will Offset Phase III Trial Costs

Preserving Early Investor Equity

Pro Forma Montana (Prior to FDA Approval)



Paid by Profits

\$25M
Phase III
Expenses

Paid by Series A

Primed For National Scale After Market Approval

Montana sales will pre-establish provider trust and prove the price-point for insurance.

First Sold Through:

 5 Main Equipment Distributors

 20k Audiologists & ENTs

\$9B US Market

Patients Currently Visiting Audiologists/ENTs with Central Hearing Loss * \$5k Every 5 Years

Later Sold Through:


 Online Longevity D2C

Safe, well-known drug, and consumer headphones ideal for telehealth

\$125B US Market

125M Americans Aged 50+ Benefiting from Cognitive Longevity * \$5k Every 5 Years

Asking For **\$3M** To Reach Phase III by 2028



\$3M

Seed Round

To Deliver in 18 Months:

Phase II human efficacy data

Real-world revenue and patient outcomes from Montana


7-10 additional patent filings on specific mechanisms

Clear line of sight to Phase III (\$25M raise) and market approval

Our Scale Is Not Limited Like Hearing Aids

LOOT can become for dementia what baby aspirin is for heart attacks.

Baby aspirin prevents 1 in 2500 heart attacks, yet many take it prophylactically



Treating Hearing loss prevents 1 in 12 dementia cases, and is twice as important for those with difficulty hearing in noise



Let's cut through the noise, and chart a course from hearing to cognitive longevity.



Sam Budoff, PhD

CEO, Co-Founder
sam@parley-neuro.com

